FOR IMMEDIATE RELEASE
Alivexis announces publication of a research article on its ground-breaking ModBind™ simulation technology
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces that a research article entitled “ModBind, a Rapid Simulation-Based Predictor of Ligand Binding and Off-Rates” by William Sinko et. al. has been published in the Journal of Chemical Information and Modeling. This article describes the methodology, validation, and application results of the initial version of the company’s ground-breaking simulation technology that enables accurate absolute ligand efficacy predictions at up to ~1,000s x faster speeds than existing methods. ModBindTM has been used extensively to accelerate drug discovery and has delivered pharma collaborations and multiple clinical candidate molecules in the company’s pipeline.
Publication information
Title: ModBind, a Rapid Simulation-Based Predictor of Ligand Binding and Off-Rates
Authors: William Sinko, Blake Mertz, Takafumi Shimizu, Taisuke Takahashi, Yoh Terada and S. Roy Kimura (Alivexis, Inc.)
Journal: Journal of Chemical Information and Modeling
DOI: 10.1021/acs.jcim.4c01805
Publication date: December 16th, 2024 (online)
【CEO S. Roy Kimura’s Comments】
“We are very excited to announce the publication of our research article on our novel ModBindTM technology. Over the past several years, we have developed this unique technology and have applied it successfully to our discovery programs and collaborations with biopharma partners, resulting in accelerated discovery of multiple clinical candidate molecules. Our method is based on a statistical thermodynamic theory that is distinct from the industry state-of-the-art, and has major advantages including enabling >100-1,000-fold shorter simulation times required for convergence and accurate predictions. We hope that this publication will stimulate discussions and innovations that would enable the efficient discovery of drug candidates for diseases with high unmet need.”
If you’d like more information about this topic, please email at info@alivexis.com